“Pfizer & BioNtech and Moderna Inc. could receive conditional European Union (EU) marketing authorization for their Covid-19 vaccines in the second half of next month,” Bloomberg reported, citing comments from the European Commission President Ursula von der Leyen.
“The European Medicines Agency is in daily contact with the US Food and Drug Administration about the evaluation of the vaccines in order to “synchronize” assessment.”
“If all proceeds with no problems, EMA tells us that the conditional marketing authorization for BioNTech and Moderna could happen as early as the second half of December 2020.”
“The Brussels-based commission will “hopefully soon” reach a vaccine-supply agreement with Moderna and is also in talks with Novavax Inc.”
Meanwhile, the EU is reportedly said to pay more than EUR9 billion for Pfizer and CureVac vaccines, Reuters reported, citing an EU official involved in the talks.
To pay EUR15.50 per dose of Pfizer coronavirus vaccine candidate.
To pay EUR10 per dose of CureVac coronavirus vaccine candidate.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.